No Data
Shanxi Zhendong Pharmaceutical (300158.SZ): has cumulatively repurchased 0.3 million shares.
Shanxi Zhendong Pharmaceutical (300158.SZ) announced that, as of November 30, 2024, the company has cumulatively repurchased 0.3 million shares of the company through the share repurchase special securities account in a centralized auction trading manner, accounting for 0.03% of the company's current total share capital. The highest fill price for repurchase was RMB 5.03 per share, while the lowest fill price was RMB 5.01 per share, with a total transaction amount of RMB 1,506,000 (excluding transaction fees).
Shareholders in Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Have Lost 8.5%, as Stock Drops 7.1% This Past Week
shanxi zhendong pharmaceutical (300158.SZ): Currently, there are no pharmaceuticals available for the treatment of dengue fever.
shandong zhendong pharmaceutical (300158.SZ) stated on the investor interaction platform on November 6 that the company currently does not have any pharmaceuticals for the treatment of dengue fever.
Financial Morning Post: The first batch of active equity funds' third-quarter reports are released, leveraged funds continue to enter the market, and margin trading balance has increased for seven consecutive trading days.
【Highlights】A-shares are expected to welcome hundreds of billions of incremental funds. After the accelerated implementation of two major innovative mmf policy tools, all parties in the market are speeding up their participation and advancing related matters. On the 18th, the People's Bank of China announced the official launch of SFISF, with an initial operation scale of 500 billion yuan. The central bank will conduct operations in batches according to the needs of participating institutions. The first batch of 20 securities and fund companies have been approved to participate, with the initial application quota exceeding 200 billion yuan. Subsequently, institutions responded quickly and actively promoted the landing of SFISF business. Starting this Monday (21st), China International Capital Corporation and GTJA.
Zhendong Pharmaceutical: Report for the third quarter of 2024
Shanxi Zhendong Pharmaceutical (300158.SZ): Plans to spend 0.05 billion yuan-0.1 billion yuan to repurchase shares.
On October 23, Gelonhui reported that shanxi zhendong pharmaceutical (300158.SZ) announced that the company plans to repurchase the company's issued Renminbi ordinary shares (A shares); the repurchased shares will be used for cancellation and reduction of registered capital; the total amount of funds for repurchasing shares is up to 100 million yuan, with a minimum of 50 million yuan; the purchase price shall not exceed 6.00 yuan/share (including the principal). The implementation period of the share repurchase shall not exceed 12 months from the date of approval of the share repurchase plan by the shareholder meeting.
Revenues Working Against Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Share Price Following 26% Dive
